Abstract: The invention relates to (among other things) oligomer-aryloxy-substituted propanamine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated aryloxy-substituted propanamine compounds.

Abstract: Provided here are methods of manufacture of viloxazine and its various salts, as well as viloxazine-related compounds, such as novel intermediate reaction products and polymorphs thereof. In particular, the methods provide a substantially pure API of viloxazine HCl while avoiding undesirable impurities. The methods further provide for separating, identifying, and characterizing novel polymorphs of viloxazine. Further provided are methods for synthesis and identification and characterization of novel intermediates of viloxazine, as well as for some important metabolites and precursors of metabolites of viloxazine.

Abstract: The invention relates to a class of novel surfactants that have utility in the recovery and/or extraction of oil.

Abstract: A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstituted and substituted C3-C3 cycloalkyl, C1-C8 linear or branched alkyl, C2-5 alkenyl, C6-C10 heteroaryl or aryl, or C3-C8 heterocyclyl which may be part unsaturated, and combinations thereof; Z is linear C2-3 alkylene; X1 is selected from NH and O; X2 is selected from unsaturated C and unsaturated S; and X3 is selected from NH and CH2; or one of X1 and X3 is a single bond; or X1 is O and X2 and X3 together are a single bond; and R7 is selected from oxo, F, Cl, Br, CN, NH2, NR92, NO2, CF3, OR9, COR9, OCOR9, COOR9, NR9COR9, CONR92SO2NR92, NR9SO2R9; and R8 is selected from C1-5 alkyl, C1-5 alkoxyl, C2-5 alkenyl or alkynyl, C6-10 aryl and C3-8 cycloalkyl and combinations thereof, which may be unsubstituted or further substituted by one or more F, Cl, Br, CN, NH2, NR32, NO2, CF3;

Abstract: This invention relates to a topical cosmetic skin care method and composition. The method and composition is for treating facial skin to cause contraction and tightening of the facial skin, by effecting contraction of the collagen of the skin using an active agent/s that induces fibroblast contraction of the extra cellular matrix of the skin. A preferred active agent is a beta-2-adrenergic receptor (beta2AR) inhibitor.

Abstract: The invention provides various methods comprising the administration of a CYP2D6 bioactive drug covalently bound to a water-soluble oligomer. Metabolism of CYP2D6 bioactive drug conjugates is diverted from CYP2D6 to alternative pathways, and the conjugates may therefore be utilized to alleviate the problems associated with interpopulation variation resulting from the genetic polymorphism in the CYP2D6 gene.

Abstract: The present invention provides various methods for the synthesis of chemical species in a microreactor environment. In some cases, reaction products of the present invention may be valuable as intermediates and/or products in pharmaceutical and polymer research. For example, the method may involve the synthesis of amino alcohols within a microchannel. Embodiment described herein may allow for reactions with significantly shorter reaction times and increased efficiency.

Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.

Abstract: The present invention relates to compounds, as well as to compositions, methods and kits comprising such compounds, for use in the treatment or prophylaxis of fibromyalgia, chronic fatigue syndrome, myofascial pain syndrome, Gulf War syndrome and related conditions, wherein the compound is a fatty acid oxidation inhibitor and/or a carbohydrate oxidation activator.

Abstract: The invention comprises an enantioselective method of preparing a compound of formula (IV): wherein n, m, R and R1 are as defined herein. Use of the compounds of formula (IV) in a method of preparing compounds of formula (IX) and novel intermediates useful in the method are also described.

Abstract: Compounds containing both photoinitiator moieties and adhesion promoting moieties and coating formulations containing them are disclosed, in particular, durable UV cured primer layers for coil coatings. One embodiment includes a coated metal surface which comprises a metal substrate with at least one surface immediately adjacent to a coating layer comprising a photoinitiator chemically bound to an adhesion promoter is disclosed.

Abstract: An 1-amido-3-(2-hydroxyphenoxy)-2-propanol derivative represented by the following formula (1), wherein cycle A may have further 1 to 4 substituents, and said substituent means a substituent selected from the group consisting of saturated or unsaturated C1-4 alkyl group, aralkyl group in which alkyl moiety has 1 to 4 carbon atoms, aryl group, halogen atom, halogenated C1-4 alkyl group, C2-5 alkanoyl group, mono or dialkylcarbamoyl group in which alkyl moiety has 1 to 4 carbon atoms, cyano group and nitro group, and the substituents at positions 3 and 6, or at positions 4 and 5 on the cycle A are different each other. Other ring may be fused at positions 3 and 4, or at positions 5 and 6 on the cycle A to form a condensed polycyclic hydrocarbon with the cycle A. R1 is alkanoyl group or aroyl group, and R2 is hydrogen atom, alkanoyl group or aroyl group, or R1 and R2 may be combined together with the N atom to form a cyclic imido group, which is useful as an intermediate of medicines, etc.

Abstract: The present invention relates to RS 1-{4-[2-(allyloxy)-ethyl]phenoxy}-3-isopropylamino propan-2-ol of the formula (1), process for preparation thereof by selective allylation of p-hydroxy phenyl ethanol and use thereof in a preparation of RS betaxolol of formula (2)

Abstract: Compounds of formula (Ia) as potent, ?1-specific beta blockers with a short duration of action in the systemic circulation, wherein R is 3?,4?-dimethoxyphenyl, R1 is hydrogen, and R2 is selected from methyl, ethyl, propyl, isobutyl and isopropyl; or R is 3?,4?-dimethoxyphenyl, R1 is selected from fluorine, chlorine and bromine, and R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl and cyclopropylmethyl; of R is 4?-methoxyphenoxy, R1 is selected from hydrogen, fluorine, chlorine and bromine, and R2 is selected from methyl, ethyl, propyl, isopropyl, isobutyl and cyclopropylmethyl; or R is 3?,4?-dimethoxyphenyl, R1 is cyano, and R2 is cyclopropylmethyl; or R is 4?-methoxyphenoxy, R1 is cyano, and R2 is isobutyl; and physiologically acceptable hydrolysable derivatives thereof having the hydroxy group in the 2-position of the 3-aminopropoxy side chain in esterified form, in their racemic and optically active forms, and their pharmaceutically acceptable acid addition salts.

Abstract: The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.

Abstract: The present invention relates to an improved process for preparation of S-(?)-betaxolol salts.

Abstract: The present invention relates to a novel compound S-(?)-1-{4-[2-(allyloxy)-ethyl] phenoxy}-3-isopropylamino propan-2-ol of formula 1 and to a process for the preparation thereof. More particularly the present invention relates to a process for preparing S-(?)-1-{4-[2-(allyloxy)-ethyl]phenoxy}-3-isopropylamino propan-2-ol of formula 1 by selective allylation of p-hydroxy phenyl ethanol.

Abstract: The invention relates to a process for providing a stable crystalline form of a fine-milled salbutamol sulfate, which can be produced, stored and used while maintaining the aerodynamic properties required for inhalation thereof, which comprises the steps of

Abstract: A readily available and inexpensive natural &agr;-amino acid is converted into a compound represented by formula (1), which is then reacted with an organometallic reagent represented by formula (2) to give an optically active 5-hydroxyoxazolidine represented by formula (3), which is then treated with an acid to provide an optically active aminoketone represented by formula (4). The product is then converted into an optically active aminoalcohol represented by formula (5) or (6) by, for example reduction.

Abstract: Substituted 1-aminobutane-3-ol compounds, methods for producing them, pharmaceutical compounds containing them, and the use of substituted 1-aminobutane-3-ol compounds for producing pharmaceutical compounds.

Abstract: The present invention provides stereoscopically-pure diastereomers of Formula I: 1

Abstract: A process for preparing optically active secondary alcohols of the general formula (3), [wherein R1 is linear lower alkyl, an aromatic ring group, or the like; A is CH2NR2R3 or the like; n is an integer of 0 to 2; and * represents an asymmetric carbon atom] by asymmetrically hydrogenating a ketone compound of the general formula (1) having nitrogenous or oxygen functional group at any of the a-, &bgr;- and &ggr;-positions, with selectivity among functional groups by the use of a ruthenium/optically active bidentate phosphine/diamine complex as the catalyst in the presence of hydrogen alone or together with a base. The optically active secondary alcohols obtained by the process are useful as drugs and intermediates for the preparation of drugs.

Abstract: The invention disclosed some derivative chemically with Hydroxyphenyl carboxylic acid and Alcohol based phenoxypropanolamine and associated alanyl-proline peptide derivatives.

Abstract: Amines are prepared by reacting aldehydes or ketones at elevated temperature under elevated pressure with nitrogen compounds selected from the group of ammonia, primary and secondary amines, and with hydrogen in the presence of a catalyst, wherein the catalytically active mass of the catalyst contains, after its preparation and before the treatment with hydrogen, 22 to 45% by weight of oxygen-containing compounds of zirconium, calculated as ZrO2, 1 to 30% by weight of oxygen-containing compounds of copper, calculated as CuO, 5 to 50% by weight of oxygen-containing compounds of nickel, calculated as NiO, where the molar ratio of nickel to copper is greater than 1, 5 to 50% by weight of oxygen-containing compounds of cobalt, calculated as CoO, 0 to 5% by weight of oxygen-containing compounds of molybdenum, calculated as MoO3, and 0 to 10% by weight of oxygen-containing compounds of aluminum and/or manganese, calculated as Al2O3 or MnO2.

Abstract: The present invention features calcilytic compounds. “Calcilytic compounds” refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

Abstract: The present invention relates to nitric acid salts with medicines active in the respiratory system pathology treatment.

Abstract: A process for the preparation of a compound of Formula (IA) or a pharmaceutically acceptable salt thereof: wherein R1 is an aryl, pyridyl, thiazolyl, phenoxymethyl or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C1-6alkoxy, C1-6alkyl, hydroxymethyl, tifluoromethyl, —NR6R6, and —NHSO2R6, where each R6 is independently hydrogen or C1-4alkyl; R2 is hydrogen or C1-6alkyl; R3 is CO2R7 where R7 is hydrogen or C1-6alkyl; R4 and R5 are independently hydrogen, C1-6alkyl or —CO2C1-6alkyl; and Y is N or CH comprising the step of preparing a diamide of Formula (II) or a pharmaceutically acceptable salt thereof: wherein R1 is an aryl, pyridyl, thiazolyl, phenoxymethyl or pyrimidyl group, optionally substituted by one or more substituents selected from the group consisting of halogen, hydroxy, C1-6alkoxy, C1-6alkyl, hydroxymethyl, trifluoromethyl, —NR6R6, and —NHSO2R6, where each R6 is independently hydrogen or C1-4

Abstract: A ligand adapted for use in a process for enantioselective reduction of unsaturated compounds carrying functional groups by a hydrogen transfer method including an optically active N-substituted chiral derivative of norephedrine and the associated process.

Abstract: Improved processes for preparation of high enantiomeric purity compounds center on resolution using simulated moving bed chromatography of a racemic precursor early in the synthesis. Resolution is effected with high enantiomeric purity, and subsequent reactions of the desired enantiomer performed with high optical specificity to maintain enantiomeric purity. The undesired enantiomer is racemized and recycled to the resolution phase to avoid loss.

Abstract: The invention relates to a method for preparing aryl ethers that are useful as antidepressants. The invention also relates to intermediates useful in the method and to methods for preparing such intermediates.

Abstract: The present invention is directed to multibinding compounds which are &bgr;3 adrenergic receptor agonists and are therefore useful in the treatment and prevention of metabolic disorders such as obesity, diabetes, and the like.

Abstract: Mannich polyols having a viscosity of from 300 to 3,500 cps (0.3 to 3.5 Pa*s) at 25° C. are prepared by admixing a phenol, an alkanolamines, and formaldehyde mixed in molar ratios of from 1:1:1 to 1:2.2:2.2 resulting in an initiator which can be alkoxylated using a mixture of ethylene oxide and propylene oxide to prepare polyols that have a nominal functionality of from 3 to 5.4.

Abstract: The invention relates to a process for the solid state synthesis of enantiopure &bgr;-aminoalcohols by preparing inclusion complexes of aryloxyepoxide with cyclodextrin by adding an epoxide in equimolar ratio in an organic solvent to an aqueous solution of cyclodextrin, reacting the cyclodextrin complex of aryloxyepoxide with a nucleophile in solid state by intimately grinding the mixture using a mortar and pestle, continuing the mixing till the starting epoxide disappeared on tic, removing excess amines under vacuum, extracting the &bgr;-aminoalcohols produced with a solvent with yields of more than 50% and enantioselectivity of upto 100%.

Abstract: A method for the preparation of 3-amino-1,2-propandiol derivatives of the formula (I) ##STR1## by reacting a compound of the formula (II) ##STR2## with RNH.sub.2, wherein R and R.sub.1 have the same meaning as given in the description. The formula (I) derivatives are .beta.-blockers used for treating hypertension.

Abstract: 3-Hydroxy-propanamine derivatives and acid salts thereof having chiral centers at the C.sub.1 and C.sub.2 positions exhibit synaptosomal reuptake inhibition of neurotransmitters, and as such represent a new class of psychotropic agents useful as antidepressants.

Abstract: Amines are prepared from primary or secondary alcohols and nitrogen compounds selected from the group of ammonia, primary and secondary amines, at from 80 to 250.degree. C. under pressures from 0.1 to 40 MPa with hydrogen in the presence of a catalyst comprising zirconium, copper and nickel, wherein the catalytically active composition comprises20-85% by weight of oxygen-containing zirconium compounds, calculated as ZrO.sub.2,1-30% by weight of oxygen-containing copper compounds, calculated as CuO,14-70% by weight of oxygen-containing nickel compounds, calculated as NiO, where the molar ratio of nickel to copper is greater than 1,0-10% by weight of oxygen-containing aluminum and/or manganese compounds, calculated as Al.sub.2 O.sub.3 and/or MnO.sub.2,and no oxygen-containing cobalt or molybdenum compounds.

Abstract: A process for preparation of 3-amino-2-hydroxy-1-propyl ether of the formula ##STR1## wherein R.sup.1 is substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heterocyclic ring, R.sup.2 and R.sup.3 are the same or different hydrogen atom, a substituted or unsubstituted alkyl, or may form a ring together with an adjacent nitrogen atom, which ring may be interrupted with nitrogen atom, oxygen atom or sulfur atom,which is characterized in reacting an epoxy compound of the formula ##STR2## wherein X is halogen, in the presence of a fluoride salt, with an alcohol and then reacting an amine.According to the above method, an intermediates for synthesis of medicines is obtained in good yield and highly optical purity.

Abstract: The present invention features calcilytic compounds. "Calcilytic compounds" refer to compounds able to inhibit calcium receptor activity. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient; and techniques which can be used to obtain additional calcilytic compounds.

Abstract: Disclosed are A N-[(fluoroalkoxy)phenoxyalkyl]benzamide compound represented by the formula (1): ##STR1## wherein R.sup.1 and R.sup.3 may be the same or different and represent a hydrogen atom, a halogen atom, a C.sub.1-4 alkyl group, a C.sub.1-4 alkoxy group, a C.sub.1-4 haloalkyl group, a C.sub.1-4 haloalkoxy group, a cyano group, a nitro group, or a hydroxy group; R.sup.2 represents a hydrogen atom, a halogen atom, a C.sub.1-4 alkyl group, or a C.sub.1-4 alkoxy group; A represents an oxygen atom, or a sulfur atom; n is an integer of 1 to 6; x is 1 to 4; y is 0 to 6; z is 2 to 9; m is 0 to 2; provided that 2x+1=y+z+m, an intermediate thereof, processes thereof and an agricultural and horticultural chemical for controlling noxious organisms containing the above-mentioned compound as an effective ingredient which is available as a nematocide, an acaricide, a fungicide, etc.

Abstract: The present invention relates to a process for the selective alkylation of intermediates of betaxolol.

Abstract: Fluorinated beta blockers, such as propranolol, are presented with amplified antioxidant effects and various levels of beta blocking effects. Mixtures are also presented of fluorinated antioxidant drugs, such as propranolol, with fluorinated antioxidant non-beta blocking analogs of the same drugs. Methods of treatment of disease by the use of the fluorinated drugs and the mixtures are presented.

Abstract: The present invention relates to a process for the selective alkylation of intermediates of betaxolol.

Abstract: Compounds of the formula ##STR1## and pharmaceutically acceptable salts thereof wherein: R.sup.1 to R.sup.9 are as defined herein and m is the integer 0 or 1.These compounds are beta 3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity, gastrointestinal diseases and achalasia.

Abstract: The present invention relates to novel tertiary amines derived from bisphenoles, diepoxides and aromatic secondary amines, to a process for their preparation and to their use as hardening accelerators for ethylenically unsaturated cold hardenable acrylic and polyester resins.

Abstract: Compounds of formula (I): ##STR1## (wherein: R.sup.0 is hydrogen, methyl or hydroxymethyl; R.sup.1 is substituted alkyl; R.sup.2 and R.sup.3 are each hydrogen, halogen, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkyl, nitro, haloalkyl, or substituted alkyl; X is oxygen or sulfur; and Ar optionally substituted phenyl or naphthyl); and pharmaceutically acceptable salts thereof have a variety of valuable pharmaceutical activities, including anti-diabetic and anti-obesity activities; in addition, they are capable of treating or preventing hyperlipemia and hyperglycemia and, by inhibiting the action of aldose reductase, they can also be effective in the treatment and prevention of complications of diabetes.

Abstract: Compounds of formula (I): ##STR1## [wherein: R.sup.1 is aryl; R.sup.2 is hydrogen, alkyl, alkoxy, halogen or cyano; R.sup.3 is a group of formula --B--NR.sup.4 R.sup.5, where R.sup.4 and R.sup.5 are independently hydrogen, alkyl or substituted alkyl or R.sup.4 and R.sup.5, together with the nitrogen to which they are attached, form a heterocycle, and B is alkylene or a group of formula --CH.sub.2 CH(OR.sup.6)CH.sub.2 --, where R.sup.6 is hydrogen, alkanoyl, substituted alkanoyl or arylcarbonyl, or a group of formula --D--R.sup.7, where D is a single bond or alkylene and R.sup.7 is a heterocycle; and A is alkylene; and pharmaceutically acceptable salts and esters thereof] are useful for the treatment and prevention of circulatory diseases and psychosis.

Abstract: A process for the preparatiion of an amine which comprises reacting a primary or secondary alcohol and a nitrogen compound selected from the group consisting of ammonia and primary and secondary amines, at temperatures of from 80.degree. to 250.degree. C. and pressures of from 1 to 400 bar using hydrogen in the presence of a zirconium/copper/nickel catalyst, wherein the catalytically active material contains from 20 to 85 wt % of oxygen-containing zirconium compounds, calculated as ZrO.sub.2, from 1 to 30 wt % of oxygen-containing compounds of copper, calculated as CuO, from 30 to 70 wt % of oxygen-containing compounds of nickel, calculated as NiO, from 0.1 to 5 wt % of oxygen-containing compounds of molybdenum, calculated as MoO.sub.3 and from 0 to 10 wt % of oxygen-containing compounds of aluminum and/or manganese, calculated as Al.sub.2 O.sub.3 or MnO.sub.2, respectively.

Abstract: A hypotensive agent and antiglaucoma agent which comprise a compound represented by the following formula: ##STR1## (wherein R.sub.1 is hydrogen, or a lower alkyl or lower alkoxy group; R.sub.2 is an isopropylamino, tert-butylamino, 2-(2-methoxyphenyl)ethyl-1-amino, 4-(2-methoxyphenyl)!-1-piperazinyl or 4-piperonyl-1-piperazinyl group, provided however that in the case of R.sub.1 being hydrogen, R.sub.2 is neither isopropylamino nor tert-butylamino group) or its pharmacologically acceptable salt.

Abstract: Substituted phenoxyhydroxy amines and derivatives thereof are described as well as methods for the preparation and pharmaceutical compositions of same, which are central nervous system agents useful in the treatment of neurological disorders including traumatic brain surgery, stroke, migraine, acute and chronic pain, epilepsy, Parkinson's disease, Alzheimer's disease, amyotropic lateral sclerosis, multiple sclerosis, psychosis, and depression.

Abstract: A method for separating enantiomers of a derivative of an aryloxipropanolamine is disclosed, characterized in that the derivative is contacted with a chiral solid-phase chromatography material containing molecular imprints of an optically pure enantiomer of the derivative to be separated.